New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Today, Benzinga's options scanner spotted 13 options trades for Amgen. This is not a typical pattern. The sentiment among ...

Lipid management for woman requires personalized care that considers sex-specific conditions across the reproductive lifespan ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ETCompany ParticipantsJames E.

Amgen Inc. closed 15.40% below its 52-week high of $346.85, which the company reached on July 25th.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of $328.00. The company’s shares c ...

HealthDay News — Childhood cancer survivors (CCS) have an increased risk for chronic kidney disease (CKD) and hypertension, according to a study published online May 19 in JAMA Network Open.